My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 187

    1.

    Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.

    Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE; Diabetes Prevention Program Research Group.

    Diabetes. 2005 Apr;54(4):1150-6.PMID: 15793255 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    [Progress in the prevention of type 2 diabetes]

    Schernthaner G.

    Wien Klin Wochenschr. 2003 Nov 28;115(21-22):745-57. Review. German. PMID: 14743578 [PubMed - indexed for MEDLINE]Related articles

    3.

    The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.

    [No authors listed]

    Diabetes Care. 1999 Apr;22(4):623-34. Erratum in: Diabetes Care 1999 Aug;22(8):1389. PMID: 10189543 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes.

    Diabetes Prevention Program Research Group, Crandall J, Schade D, Ma Y, Fujimoto WY, Barrett-Connor E, Fowler S, Dagogo-Jack S, Andres R.

    J Gerontol A Biol Sci Med Sci. 2006 Oct;61(10):1075-81.PMID: 17077202 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program.

    Franks PW, Jablonski KA, Delahanty L, Hanson RL, Kahn SE, Altshuler D, Knowler WC, Florez JC; Diabetes Prevention Program Research Group.

    Diabetologia. 2007 Dec;50(12):2451-60. Epub 2007 Sep 27.PMID: 17898990 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    An update on the Diabetes Prevention Program.

    Ratner RE; Diabetes Prevention Program Research.

    Endocr Pract. 2006 Jan-Feb;12 Suppl 1:20-4. Review.PMID: 16627375 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.

    Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, Andres R, Saudek C, Edelstein SL, Arakaki R, Murphy MB, Shamoon H; Diabetes Prevention Program Research Group.

    Diabetes. 2005 Aug;54(8):2404-14.PMID: 16046308 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

    Roberts VL, Stewart J, Issa M, Lake B, Melis R.

    Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

    9.

    TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.

    Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA.

    Control Clin Trials. 1998 Apr;19(2):217-31.PMID: 9551285 [PubMed - indexed for MEDLINE]Related articles

    10.

    Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.

    Florez JC, Jablonski KA, Sun MW, Bayley N, Kahn SE, Shamoon H, Hamman RF, Knowler WC, Nathan DM, Altshuler D; Diabetes Prevention Program Research Group.

    J Clin Endocrinol Metab. 2007 Apr;92(4):1502-9. Epub 2007 Jan 9.PMID: 17213274 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects.

    Yatagai T, Nakamura T, Nagasaka S, Kusaka I, Ishikawa SE, Yoshitaka A, Ishibashi S.

    Diabetes Res Clin Pract. 2004 Jan;63(1):19-26.PMID: 14693409 [PubMed - indexed for MEDLINE]Related articles

    12.

    The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program.

    Moore AF, Jablonski KA, Mason CC, McAteer JB, Arakaki RF, Goldstein BJ, Kahn SE, Kitabchi AE, Hanson RL, Knowler WC, Florez JC; Diabetes Prevention Program Research Group.

    J Clin Endocrinol Metab. 2009 Feb;94(2):449-55. Epub 2008 Nov 18.PMID: 19017751 [PubMed - indexed for MEDLINE]Related articles

    13.

    Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.

    Scheen AJ, Lefèbvre PJ.

    Diabetes Care. 1999 Sep;22(9):1568-77. Review.PMID: 10480527 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

    Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

    Clin Ther. 2005 Sep;27(9):1383-91.PMID: 16291411 [PubMed - indexed for MEDLINE]Related articles

    15.

    The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.

    Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S; Diabetes Prevention Program Research Group.

    Ann Intern Med. 2005 Apr 19;142(8):611-9.PMID: 15838067 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group.

    N Engl J Med. 2002 Feb 7;346(6):393-403.PMID: 11832527 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study.

    Snitker S, Watanabe RM, Ani I, Xiang AH, Marroquin A, Ochoa C, Goico J, Shuldiner AR, Buchanan TA; Troglitazone in Prevention of Diabetes (TRIPOD) study.

    Diabetes Care. 2004 Jun;27(6):1365-8.PMID: 15161789 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.

    Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP.

    Diabetes. 2002 Sep;51(9):2796-803.PMID: 12196473 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study.

    Stakos DA, Schuster DP, Sparks EA, Wooley CF, Osei K, Boudoulas H.

    J Cardiol. 2003 Apr;41(4):183-90.PMID: 12728539 [PubMed - indexed for MEDLINE]Related articles

    20.

    Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.

    Eddy DM, Schlessinger L, Kahn R.

    Ann Intern Med. 2005 Aug 16;143(4):251-64.PMID: 16103469 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity